PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32356320-0	2020	Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.	Decitabine	144-154	CD33 molecule	Homo sapiens	10-14	
32303428-2	2020	We previously showed that decitabine enhances expression of NKG2D ligands in AML with additive cytotoxicity when NK cells and Fc (fragment crystallizable region)-engineered CD33 monoclonal antibody (CD33mAb) was used.	Decitabine	26-36	CD33 molecule	Homo sapiens	173-177	
32303428-10	2020	Importantly, CD33mAb-dependent enhanced cytotoxicity by mbIL-21 NK cells was maintained in AML cells from patients even 24 days post-decitabine treatment.	Decitabine	133-143	CD33 molecule	Homo sapiens	13-17	
27013443-0	2016	Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.	Decitabine	0-10	CD33 molecule	Homo sapiens	25-29